RT Journal Article
SR Electronic
T1 A HER 1-2 Punch: Dual EGFR Targeting Deals Resistance a Deadly Blow
JF Cancer Discovery
JO CANCER DISCOVERY
FD American Association for Cancer Research
SP 991
OP 994
DO 10.1158/2159-8290.CD-14-0791
VO 4
IS 9
A1 Gibbons, Don L.
A1 Byers, Lauren Averett
YR 2014
UL http://cancerdiscovery.aacrjournals.org/content/4/9/991.abstract
AB Summary: Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer. Cancer Discov; 4(9); 991–4. ©2014 AACR. See related article by Janjigian et al., p. 1036